News Articles

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition LONDON -Friday 29 April 2022

Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Siggi Olafsson, Hikma’s CEO, said: “Hikma continues to make strategic progress, positioning the business for future growth through new product launches,...

Hikma Ventures Participates in USD 44 Million Financing Round for Altibbi to Expand the Platform’s Reach across... -Tuesday 29 March 2022

Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures, has participated in the Series B financing round for Altibbi; the leading publisher of Arabic medical content globally - with two million...

Hikma delivers another year of profitable growth in 2021 and announces share buyback -Thursday 24 February 2022

Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its preliminary audited results for the year ended 31 December 2021. In 2021, group revenue grew 9% to $2.553 billion ($2.341 Billion in 2020), reflecting a good performance from...

Hikma expands licensing agreement with Celltrion for Remsima® subcutaneous formulation in MENA -Monday 7 February 2022

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement with South Korea-based Celltrion, Inc. and Celltrion Healthcare, Inc. (Celltrion) for Remsima® subcutaneous (SC), the first subcutaneous formulation of infliximab. The...

Hikma signs license agreement with Medicine Patent Pool for molnupiravir -Thursday 20 January 2022

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it has entered into a license agreement with Medicine Patent Pool (MPP) for molnupiravir, MSD’s[1] investigational oral COVID-19 antiviral medicine, in the Middle East and North Africa (MENA) region....

Hikma and Winterlight Labs PoC Collaboration -Tuesday 23 November 2021

Hikma Pharmaceuticals PLC (‘Hikma’), the multinational pharmaceutical company, announces a collaboration agreement with Winterlight Labs, Inc., a Hikma Ventures portfolio company, to conduct a Proof-of-Concept (PoC) study to validate Winterlight Labs’ speech-based biomarkers for...

Hikma and Almirall enter an exclusive licensing agreement to market FinjuveTM in the Middle East and North... -Monday 1 November 2021

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that it has entered into an exclusive licensing agreement with Almirall S.A., a global biopharmaceutical company, to commercialise FinjuveTM in certain Middle East and North Africa (MENA) markets....

Hikma strengthens US Injectables business through acquisition of Custopharm -Monday 27 September 2021

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company and one of the largest suppliers of generic injectable medicines in the US, today announces that it has agreed to acquire Custopharm Inc. (‘Custopharm’) from Water Street Healthcare Partners (‘Water...

Hikma delivers another strong financial and operational performance, and improves FY outlook for Generics -Friday 6 August 2021

Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its interim results for the six months ended 30 June 2021. Siggi Olafsson, Chief Executive Officer of Hikma, said:  “Once again, we have benefited from the resilience of our...

Hikma and Melinta Therapeutics sign exclusive licensing agreement for two novel anti-infectives for the Middle East and... -Thursday 29 April 2021

Hikma Pharmaceuticals PLC (Hikma) and Melinta Therapeutics (Melinta) today announced they have entered into an exclusive licensing agreement for Vabomere® (meropenem and vaborbactam) and Orbactiv® (oritavancin), two novel anti-infective injectable products, for the Middle East and North Africa...

Hikma continues strong 2020 performance and updates full year guidance -Thursday 5 November 2020

Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Siggi Olafsson, Hikma’s CEO, said: “Hikma is performing well, maintaining the positive momentum of the first half.  The breadth of our portfolio, the flexibility...

Results 1-11 of 11